ZINGER KEY POINTS
- Companies are reportedly seeking to implement price rise on over 500 drugs in the U.S. next month.
- Drugmakers have generally restrained price increases to 10% or lower, steering away from the sharp hikes.
Just as large pharma companies prepare a showdown with Medicare’s newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on more than 500 drugs in the U.S. in early January.
Companies including Pfizer Inc, Sanofi SA, and Takeda Pharmaceutical Co Ltd are expected to participate in the move that comes as part of the pharmaceutical industry’s preparation for the forthcoming publication of significantly discounted prices for ten high-cost drugs by the Biden Administration in September.
Additionally, the industry faces challenges posed by elevated inflation rates and escalating manufacturing costs.
Healthcare research firm 3 Axis Advisors’ data indicates that amidst these developments, three companies, including GSK Plc, are anticipated to decrease prices on at least 15 unique drugs in January, Reuters reported.
This follows GlaxoSmithKline’s recent announcement of price reductions on specific asthma, herpes, and anti-epileptic drugs slated for 2024.
The evolving landscape also aligns with efforts by various companies earlier this year to decrease insulin prices to avoid penalties outlined in the 2021 American Rescue Plan Act.
Despite heightened inflation rates, drugmakers have generally restrained price increases to 10% or lower, steering away from the sharp hikes seen in the past.
Antonio Ciaccia, President of 3 Axis, anticipates significant impacts on former blockbuster insulin drugs due to the prevailing policy changes.
The adjustments in drug prices primarily affect list prices, excluding rebates to pharmacy benefit managers and other discounts. Despite concerns and changing dynamics, drugmakers have maintained a consistent median price increase of around 5% since 2019, indicating a cautious approach.
Disclaimer:Â This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
—
Originally Posted December 29, 2023 – Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
Disclosure: Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Disclosure: Interactive Brokers
Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from Benzinga and is being posted with its permission. The views expressed in this material are solely those of the author and/or Benzinga and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Join The Conversation
If you have a general question, it may already be covered in our FAQs. If you have an account-specific question or concern, please reach out to Client Services.